(October 23, 2018) Olaparib, or Lynparza, was shown to increase progression-free survival (PFS) by almost three years in an ongoing trial known as SOLO-1. The women in the study are BRCA 1 or 2 positive and newly diagnosed with an advanced stage of high grade serous or endometroid ovarian cancer, primary peritoneal, or fallopian tube … Continued
(October 22, 2018) A team at the University of Illinois at Chicago, including OCRA grantee Matthew Dean, PhD, recently discovered the role that cancer cells have on their immediate environment. The research was funded in part by OCRA. More specifically, they found evidence that ovarian cancer cells formed in the fallopian tube change how the … Continued
(October 19, 2018) A retroactive study using SEER, or Surveillance, Epidemiology, and End Results, looked at the trends in ovarian cancer from 1983 to 2012. In almost 3 decades, the incidence of ovarian cancer per 100,000 fell from 13.7 to 10.8 and the median survival increased from 34 months to 52 months. When this survival … Continued
(October 18, 2018) Longtime OCRA Scientific Advisory Committee member and former grantee Kunle Odunsi, MD, PhD, has been elected to the National Academy of Medicine—a distinguished lifetime designation that is considered one of the highest honors in health and medicine. Members are elected by their peers based on their contributions to the advancement of the … Continued
(October 15, 2018) This month in Nature, researchers from Weill Cornell published a study that helps to explain why the body’s natural immune response struggles to fight back against ovarian cancer. Using ovarian tumors from humans and mice, they found that T cells, vital to destroying cancerous cells, are inhibited because of the tumor’s effect … Continued
(October 11, 2018) The BMJ recently published a study from Denmark about the effect that newer birth control pills have on ovarian cancer risk. Researchers focused on two kinds of pills, those which contained both estrogen and progestogen or those which only had progestogen. In this study, rather than having a specific number of people … Continued
(October 9, 2018) A study, published in JAMA Oncology, followed about 200,000 women over the course of 25 years in order to track their use of analgesics. A little over one-thousand of those women developed epithelial ovarian cancer within that time frame. Although researchers didn’t find any significant differences in risk when they evaluated aspirin … Continued
(October 2, 2018) A study by the Mayo Clinic earlier this year aimed to increase the amount of genetic counseling referrals to epithelial ovarian cancer patients by supplying patients with a Genetics Referral Toolkit. The research was funded by OCRA through the SU2C Ovarian Cancer Dream Team. The toolkit included a checklist, a way to … Continued
(October 1) OCRA’s inaugural Super September shopping event took place on September 27-28 at Pier 17 in Manhattan. Guests enjoyed discount designer shopping, a special musical performance from the hit Broadway show Dear Evan Hansen, and so much more.
(October 1, 2018) We’re shortening our name, to make it easier to say and easier to write. OCRFA is now Ovarian Cancer Research Alliance (OCRA). You can find us at ocrahope.org, and on social media at @OCRAHOPE.
(September 21, 2018) In an international collaboration funded in part by OCRFA, published recently in Cell, researchers used proteomics, the large-scale study of proteins, to identify an important indicator for treatment and disease-free survival in patients with high grade serous ovarian cancer. The biomarker, known as CT45, is associated with better response to chemotherapy and … Continued
(September 19, 2018) Researchers at the University of Washington recently made a breakthrough in identifying and confirming variants of the BRCA1 mutation, a gene mutation that increases a woman’s risk of breast and ovarian cancers. Although the most common BRCA1 and BRCA2 mutations are already known to increase risk, there are thousands of variants of … Continued
Get email updates about research news, action alerts, and ways to join the fight.
